Bone Marrow Grafting and Cellular Therapy for Leukemia and Lymphoma

$2,936,016P01FY2025CANIH

Stanford University, Stanford CA

Investigators

Linked publications & trials

Paper 38996463 Paper 38968138 Paper 38865660 Paper 38498731 Paper 38083878 Paper 37196642 Paper 37126659 Paper 36749920 Paper 36584673 Paper 36097223 Paper 35790103 Paper 35102136 Paper 35042013 Paper 34705520 Paper 34671121 Paper 34521106 Paper 34448832 Paper 34404616 Paper 34376537 Paper 34363960 Paper 34312556 Paper 34133196 Paper 33892183 Paper 33570626 Paper 33512414 Paper 33156925 Paper 33087332 Paper 32898248 Paper 32558897 Paper 32343962 Paper 32243795 Paper 32117218 Paper 32081787 Paper 31935280 Paper 31797584 Paper 31427277 Paper 31366893 Paper 31211693 Paper 30951840 Paper 30545830 Paper 30119012 Paper 29620581 Paper 29572391 Paper 29371107 Paper 29296777 Paper 28416503 Paper 28357677 Paper 28104514 Paper 27815002 Paper 27802969 Paper 27760760 Paper 27492312 Paper 27365426 Paper 27365424 Paper 27338637 Paper 26991267 Paper 26902899 Paper 26880996 Paper 26792747 Paper 26779417 Paper 26693907 Paper 26659815 Paper 26653364 Paper 26494841 Paper 26250581 Paper 26146806 Paper 26055304 Paper 25994967 Paper 25893457 Paper 25812839 Paper 25795920 Paper 25766725 Paper 25572032 Paper 25412851 Paper 25311657 Paper 25293774 Paper 25030062 Paper 24879117 Paper 24781195 Paper 24769317 Paper 24607552 Paper 24475140 Paper 24068494 Paper 24030387 Paper 23921175 Paper 23835699 Paper 23685278 Paper 23652802 Paper 23419792 Paper 23382226 Paper 22939368 Paper 22932801 Paper 22685402 Paper 22563089 Paper 22545133 Paper 22440752 Paper 22174155 Paper 22161683 Paper 22160699 Paper 22013055

Abstract

Project Summary/Abstract: Hematopoietic cell transplantation (HCT) and cellular therapies are effective treatments for a broad range of hematological malignances, representing the first successful and widely applied cellular therapy for cancer. In this revised Program Project Grant competitive renewal (years 34-38), we will probe the cellular basis of transplantation biology (Project 1 and 3) and cell therapies with novel cellular populations, including iNKT cells (Project 1), CAR T cells (Projects 2 and 3), Treg cells (Project 2) and novel antibody constructs (Project 4). The overall goals of our Program Project Grant are to develop a more robust fundamental understanding of transplantation biology and cellular therapies and to address the major challenges of HCT including reducing transplantation risks, preventing graft-vs-host-disease (GvHD) and disease relapse. We will utilize innovative animal modeling, comprehensive biological and molecular analysis, novel imaging and biologically focused translational clinical trials. Our Program involves four highly interactive Projects focusing on: addressing transplantation risk (Projects 3 and 4), the biology and prevention of GVHD (Projects 1, 2 and 3), prevention and treatment of disease relapse with iNKT cells (Project 1), CAR T cells (Project 2 and 3) and targeted immunotherapy strategies focused on the stem cell antigen CD117 (Project 4). These Projects are supported by 3 Cores (Administration, Biostatistics and Data Management and Correlative Sciences). Through our highly interactive Program Project, we will gain novel insights into the biology of HCT and cellular therapies and develop innovative strategies to improve outcomes for patients with hematological malignancies. The knowledge gained has profound implications for extending these therapies to other cancers and for the treatment of patients with a broad range of immunological conditions such as autoimmune disorders and organ transplantation.

View original record on NIH RePORTER →